Risk of infectious complications in patients taking glucocorticosteroids.
Risk of infectious complications in patients taking glucocorticosteroids.
复制标题
服用糖皮质激素的患者出现感染并发症的风险。
DOI：
--
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
F. Frey
中科院分区：
文献类型：
--
作者：
A. Stuck;C. Minder;F. Frey
通过汇集71个对照临床试验的数据，计算了皮质类固醇治疗和后续感染之间的关联。在随机分配给全身皮质类固醇的2,111名患者中，感染并发症的总发生率为12.7%，在2,087名对照组中为8.0%(相对风险[RR]为1.6；95%可信区间[CI]为1.3-1.9；P<.001)。神经系统疾病患者的感染风险特别高(RR，2.8；95%CI，1.9-4.3；P<.001)，而肠道疾病(RR，1.4；95%CI，1.1-1.7；P=.02)、肝脏疾病(RR，1.4；95%CI，0.9-2.3；P=0.25)和肾脏疾病(RR>1；P=0.03)患者感染风险较小。在每日剂量低于10毫克或累积剂量低于700毫克的强的松患者中，这一比例没有增加。随着剂量的增加，服用皮质类固醇的患者和服用安慰剂的患者感染并发症的发生率增加，这一发现表明，在临床实践中观察到的与类固醇相关的感染并发症不仅与皮质类固醇有关，而且与潜在的疾病状态有关。
The association between corticosteroid therapy and subsequent infections was calculated by pooling data from 71 controlled clinical trials. The overall rate of infectious complications was 12.7% in the 2,111 patients randomly allocated to systemic corticosteroids and 8.0% in the 2,087 controls (relative risk [RR], 1.6; 95% confidence interval [CI], 1.3-1.9; P less than .001). The risk of infection was particularly high in patients with neurologic diseases (RR, 2.8; 95% CI, 1.9-4.3; P less than .001) and less pronounced in patients with intestinal (RR, 1.4; 95% CI, 1.1-1.7; P = .02), hepatic (RR, 1.4; 95% CI, 0.9-2.3; P = .25), and renal (RR greater than 1; P = .03) diseases. The rate was not increased in patients given a daily dose of less than 10 mg or a cumulative dose of less than 700 mg of prednisone. With increasing doses the rate of occurrence of infectious complications increased in patients given corticosteroids as well as in patients given placebo, a finding suggesting that not only the corticosteroid but also the underlying disease state account for the steroid-associated infectious complications observed in clinical practice.
狗体内稳态时泼尼松龙的清除率。
DOI：
--
发表时间：
1980
期刊：
The Journal of pharmacology and experimental therapeutics
影响因子：
--
作者：
Frey,FJ;Frey,BM;Greither,A;Benet,LZ
通讯作者：
Benet,LZ